» Articles » PMID: 35469328

Gender-Based Long-Term Outcomes After Revascularization for Three-Vessel Coronary Disease: A Propensity Score-Matched Analysis of a Large Cohort

Overview
Publisher Dove Medical Press
Specialty Geriatrics
Date 2022 Apr 26
PMID 35469328
Authors
Affiliations
Soon will be listed here.
Abstract

Objective: To investigate the impact of gender on long-term outcomes after revascularization in patients with three-vessel disease (TVD), a severe and challenging subtype of coronary artery disease.

Methods: This was a single center retrospective cohort study. A total of 3776 patients with TVD who underwent revascularization between 2013 and 2018 were analyzed and were divided into the female group (n = 1039, 27.5%) and the male group (n = 2737, 72.5%). We performed a 1:2 propensity score matching (PSM) to balance the baseline characteristics, and a total of 1506 (504 matched pairs) patients were created after undertaking PSM. The primary outcome was the frequency of major adverse cardiac and cerebrovascular events (MACCE) including all-cause death, myocardial infarction, repeat revascularization, stroke, and readmission for angina pectoris or heart failure. The secondary outcome was the incidence of all-cause death.

Results: Through 2.4-year follow-up, no significant differences in MACCE (25.8% vs 27.5%, p = 0.279) and all-cause death (2.1% vs 2.2%, p = 0.888) were observed between the two cohorts. Similar results as with the early detection were obtained in propensity-matched patients. Multivariable analysis revealed that female gender (hazard ratio 0.99, 95% confidence interval 0.88-1.17, p = 0.820) was not an independent predictor of MACCE but percutaneous coronary intervention (compared with coronary artery bypass graft surgery), hypertension, diabetes mellitus, atrial fibrillation, left main trunk involvement and left ventricular ejection fraction ≤40% were independently associated with a higher MACCE rate in these patients.

Conclusion: For patients with TVD after coronary revascularization, there were no gender-based differences in the long-term outcomes and female gender was not an independent predictor of MACCE.

Citing Articles

Long-Term Outcomes of Sex Differences in Three-Vessel Coronary Disease with Different Treatment Strategies: A Large Cohort Study.

Li J, Jiang L, Xu L, Tian J, Feng X, Wang D Glob Heart. 2024; 19(1):57.

PMID: 38973986 PMC: 11225599. DOI: 10.5334/gh.1333.


Protective role of arachidonic acid against diabetic myocardial ischemic injury: a translational study of pigs, rats, and humans.

Lv Y, Li K, Wang S, Wang X, Yue G, Zhang Y Cardiovasc Diabetol. 2024; 23(1):58.

PMID: 38336692 PMC: 10858581. DOI: 10.1186/s12933-024-02123-3.


Prognostic Value of Fibrinogen-to-Albumin Ratio in Coronary Three-Vessel Disease.

Li X, Wang Z, Zhu Y, Lv H, Zhou X, Zhu H J Inflamm Res. 2023; 16:5767-5777.

PMID: 38059151 PMC: 10697142. DOI: 10.2147/JIR.S443282.


Systemic Immune-Inflammation Index Predicts Long-Term Outcomes in Patients with Three-Vessel Coronary Disease After Revascularization: Results from a Large Cohort of 3561 Patients.

Zhao J, Lv H, Yin D, Zhou X, Zhu H, Guo L J Inflamm Res. 2022; 15:5283-5292.

PMID: 36120186 PMC: 9480584. DOI: 10.2147/JIR.S385990.

References
1.
Guo L, Lv H, Zhong L, Wu J, Ding H, Xu J . Gender Differences in Long-Term Outcomes of Medical Therapy and Successful Percutaneous Coronary Intervention for Coronary Chronic Total Occlusions. J Interv Cardiol. 2019; 2019:2017958. PMC: 6766257. DOI: 10.1155/2019/2017958. View

2.
Lansky A, Hochman J, Ward P, Mintz G, Fabunmi R, Berger P . Percutaneous coronary intervention and adjunctive pharmacotherapy in women: a statement for healthcare professionals from the American Heart Association. Circulation. 2005; 111(7):940-53. DOI: 10.1161/01.CIR.0000155337.50423.C9. View

3.
Shaw L, Bugiardini R, Merz C . Women and ischemic heart disease: evolving knowledge. J Am Coll Cardiol. 2009; 54(17):1561-75. PMC: 2789479. DOI: 10.1016/j.jacc.2009.04.098. View

4.
Duvernoy C, Smith D, Manohar P, Schaefer A, Kline-Rogers E, Share D . Gender differences in adverse outcomes after contemporary percutaneous coronary intervention: an analysis from the Blue Cross Blue Shield of Michigan Cardiovascular Consortium (BMC2) percutaneous coronary intervention registry. Am Heart J. 2010; 159(4):677-683.e1. DOI: 10.1016/j.ahj.2009.12.040. View

5.
Hueb W, Lopes N, Gersh B, Soares P, Ribeiro E, Pereira A . Ten-year follow-up survival of the Medicine, Angioplasty, or Surgery Study (MASS II): a randomized controlled clinical trial of 3 therapeutic strategies for multivessel coronary artery disease. Circulation. 2010; 122(10):949-57. DOI: 10.1161/CIRCULATIONAHA.109.911669. View